Assaf Ryan D, Morris Meghan D, Straus Elana R, Martinez Priest, Philbin Morgan M, Kushel Margot
Benioff Homelessness and Housing Initiative, University of California, San Francisco.
Division of Health Equity and Society, Department of Medicine, University of California, San Francisco.
JAMA. 2025 Apr 8;333(14):1222-1231. doi: 10.1001/jama.2024.27922.
The lack of representative research on homelessness risks mischaracterizing and misrepresenting the prevalence of illicit substance use.
To estimate the population prevalence and patterns of illicit substance use, treatment, nonfatal overdose, and naloxone possession among people experiencing homelessness in 1 US state.
DESIGN, SETTING, AND PARTICIPANTS: This representative survey study of adults experiencing homelessness from October 2021 to November 2022 in 8 California counties used multistaged probability-based sampling and respondent-driven sampling. Eligible individuals were 18 years or older and met the federal definition of homelessness.
The primary outcome measures included lifetime and past-6-month illicit substance use and substance type (methamphetamine, nonprescription opioids, or cocaine). Lifetime and current substance use treatment, unmet treatment need, types of treatments received, nonfatal overdose (lifetime and current episode of homelessness), and current possession of naloxone were measured. Population prevalence estimates with 95% Wald CIs were calculated using survey replicate weights.
Of 3865 individuals approached, 3042 (79%) participated and an additional 158 participants were recruited through respondent-driven sampling. Among 3200 participants, the mean age was 46.1 (95% CI, 45.3-46.9) years, 67.3% (95% CI, 65.2%-69.3%) were cisgender male, and there were similar proportions of Black and African American, Hispanic and Latine, and White participants. Overall, an estimated 65.3% (95% CI, 62.2%-68.4%) of participants used illicit drugs regularly (≥3 times per week) in their lifetime; 41.6% (95% CI, 39.4%-43.8%) began using regularly before their first episode of homelessness and 23.2% (95% CI, 20.5%-25.9%) began using regularly after. In the past 6 months, an estimated 37.1% (95% CI, 32.9%-41.3%) of participants reported regular use of any drug; 33.1% (95% CI, 29.4%-36.7%) reported use of methamphetamines, 10.4% (95% CI, 7.9%-12.9%) reported use of opioids, and 3.2% (95% CI, 1.8%-4.6%) reported use of cocaine. In their lifetime, an estimated 25.6% (95% CI, 22.8%-28.3%) injected drugs and 11.8% (95% CI, 9.8%-13.8%) injected drugs in the past 6 months. Among those with any regular lifetime use, an estimated 6.7% (95% CI, 3.8%-9.5%) of participants were currently receiving treatment. Of those with any regular use in the last 6 months, an estimated 21.2% (95% CI, 17.9%-24.5%) reported currently wanting but not receiving treatment. An estimated 19.6% (95% CI, 17.4%-21.8%) of participants had a nonfatal overdose in their lifetime and 24.9% (95% CI, 21.3%-28.5%) currently possessed naloxone.
In a representative study of adults experiencing homelessness in California, there was a high proportion of current drug use, history of overdose, and unmet need for treatment. Improving access to treatment tailored to the needs of people experiencing homelessness could improve outcomes.
缺乏关于无家可归者的代表性研究可能会错误地描述和呈现非法药物使用的流行情况。
估计美国一个州无家可归者中非法药物使用、治疗、非致命过量用药及纳洛酮持有情况的总体流行率和模式。
设计、地点和参与者:这项针对2021年10月至2022年11月加利福尼亚州8个县成年无家可归者的代表性调查研究采用了多阶段概率抽样和应答者驱动抽样。符合条件的个体年龄在18岁及以上,且符合联邦无家可归的定义。
主要结局指标包括终生及过去6个月的非法药物使用情况和药物类型(甲基苯丙胺、非处方阿片类药物或可卡因)。测量了终生及当前的药物使用治疗情况、未满足的治疗需求、接受的治疗类型、非致命过量用药(终生及当前无家可归期间)以及当前纳洛酮持有情况。使用调查重复权重计算95% Wald置信区间的总体流行率估计值。
在3865名被接触者中,3042人(79%)参与,另外通过应答者驱动抽样招募了158名参与者。在3200名参与者中,平均年龄为46.1岁(95%置信区间,45.3 - 46.9岁),67.3%(95%置信区间,65.2% - 69.3%)为顺性别男性,黑人和非裔美国人、西班牙裔和拉丁裔、白人参与者比例相近。总体而言,估计65.3%(95%置信区间,62.2% - 68.4%)的参与者终生定期使用非法药物(每周≥3次);41.6%(95%置信区间,39.4% - 43.8%)在首次无家可归之前开始定期使用,23.2%(95%置信区间,20.5% - 25.9%)在首次无家可归之后开始定期使用。在过去6个月中,估计37.1%(95%置信区间,32.9% - 41.3%)的参与者报告定期使用任何药物;33.1%(95%置信区间,29.